
Statistical Trends in Workplace Drug Testing


st Diagnostic

R. H. Barry Sample, Ph.D. Director of Science and Technology Employer Solutions Quest Diagnostics Incorporated

3/6/2007









FMSS Detail


		Jan-Feb
2005	2006	2007
1.0%	0.9%	1.1%
2.1%	1.9%	1.8%
3.3%	3.2%	2.5%
	1.0% 2.1%	1.0% 0.9% 2.1% 1.9%


Quest Diagnostics







	Percent of Specimens Tested by Testing Reason, 2001-2005					
		FMSS (N=4.7 million)	GW (N=23 million)			
	Pre- Employment	45%	78%			
cs	Random	43%	9%			
gnosti	Other	12%	13%			
Quest Diagnostics		3/6/2007	Quest Diagnostics			







Amphetamine Class Positivity (FMSS - 1000/500)Jan-May 2003 2005 2006 2002 2004 N (Millions) Overall Amp Methamp 1.2 0.29% 0.21% 0.21% 0.14% 1.2 0.29% 0.22% 0.22% 1.2 0.31% 0.24% 0.23% 0.5 0.28% 0.23% 0.18% 0.28% Quest Diagnostics Both Amp & Methamp 0.16% 0.18% 0.12% Quest Diagnostics









Marijuana Positivity Changes

	2003	2004	2005
N (GW-50/15)	5.1	5.2	5.4
Total Positive	0.1%	-3.3%	-12.0%
N (GW-100/15)	0.4	0.3	0.3
Total Positive	-9.0%	-4.0%	-12.9%
N (GW-20/15)	0.1	0.1	0.1
Total Positive	4.9%	0.3%	-21.8%
N (FMSS)	1.3	1.3	1.3
Total Positive	-16.2%	-6.9%	-7.1%

6/2007



Laboratory Detection of Devices and Products Used to Defeat Drug Tests

- Cleansing Agents/Detoxifiers
 - ◆ Primarily cause dilution
 - ◆ Creatinine & specific gravity
- Oxidants/Adulterants
 - ◆ pH
 - ◆ Oxidizing Adulterants
 - ◆ Aldehydes
 - ◆ Surfactants
- Devices

Quest Diagnostics

• No laboratory methods of detection!

3/6/200



Legal Status

■ Congressional Hearing in May 2005 "Subversion of Drug Testing Programs"

Subcommittee on Oversight and Investigations House Energy and Commerce Committee

- 9 Drug-testing industry and government witnesses
- ♦ 3 Witnesses that sell/manufacture products designed to defeat drug tests

http://energycommerce.house.gov/108/Hearings/05172 005hearing1525/hearing.htm#List

■ State laws

£



Diagnostics

State Laws

- Scope
 - · Attempt to defraud drug test
 - Manufacturing products intended to defraud drug test
 - Selling products intended to defraud drug test
 - Transporting products intended to defraud drug test
 - Manufacturing or providing synthetic/human urine to defraud drug
- Penalties

Quest Diagnostics

Quest Diagnostics

- Generally, misdemeanors (fines \$500-\$5000)
- Felony in several states (fines \$5000-\$10000)
- Several permit imprisonment



State with Laws Regarding Use or Sale of Products Intended to Defeat Drug Tests

1. Arkansas 2. Illinois

8. North Carolina 9. Oklahoma

3. Kentucky

10. Oregon 11. Pennsylvania


4. Louisiana 5. Maryland

12. South Carolina

6. Nebraska 7. New Jersey 13. Texas

14. Virginia






FMSS - Adulterated

			Jan-Feb
Type	2005	2006	2007
TDP	0.00%	0.00%	0.03%
DOT	0.01%	0.00%	0.00%
NRC	0.01%	0.01%	0.01%


Quest Diagnostics



FMSS - Substituted

			Jan-Feb
Туре	2005	2006	2007
TDP	0.18%	0.09%	0.13%
DOT	0.05%	0.05%	0.04%
NRC	0.03%	0.03%	0.02%

Quest Diagnos



FMSS - Dilute

S
ci i
≃ .
00
~
\simeq
_
50
Oin I
ಡ
$\overline{}$
_
=
2.0
ല

Quest Diagnostics

			Jan-Feb
Туре	2005	2006	2007
TDP	2.36%	1.72%	1.43%
DOT	2.36%	2.26%	2.01%
NRC	0.76%	0.70%	0.75%


Quest Diagnostics

Initial Test Detection Rates for Cocaine Metabolite and Marijuana Metabolite

		Drug Detection Rate	Creatinine <20 mg/dL
Overall			6.0%
Marijuana Metabolite	Below Cutoff	2.6%	14.7%
	Above Cutoff	3.5%	11.7%
Cocaine	Below Cutoff	1.0%	8.1%
Metabolite	Above Cutoff	0.9%	10.2%

- Similar prevalence of specimens containing drug above and below cutoff
- Higher incidence of low (<20 mg/dL) creatinine in specimens that contain marijuana metabolite below cutoff (*donor may be* viewed as having successfully diluted?)





FMSS - Invalid

				Jan-Feb
	Туре	2005	2006	2007
	TDP	0.17%	0.26%	0.20%
3	DOT	0.14%	0.12%	0.09%
	NRC	0.08%	0.08%	0.09%
9				

Quest Diagnostics

Invalid Reasons: FMSS

	2004	2005	2006	Jan-Feb 2007
N (Thousands)	1.0	1.5	1.6	0.3
Bottle	8%	4%	4%	7%
Characteristics	0.6%	0.3%	0.8%	0.7%
Creatinine	17%	9%	15%	9%
GCMS	11%	6%	6%	6%
Immunoassay	19%	17%	14%	14%
Oxidant Activity	12%	26%	27%	33%
pH	32%	22%	20%	20%
Specific Gravity	6%	19%	17%	15%

Quest Diagnosti

Invalid Reasons:	FMSS Detail
Oct 2006 – Feb	2007


	TDP	DOT	NRC
N (Thousands)	0.1	0.7	0.0
Bottle	0%	5%	10%
Characteristics	1.6%	1.0%	0.0%
Creatinine	0%	13%	5%
GCMS	0%	6%	0%
Immunoassay	2%	12%	30%
Oxidant Activity	29%	34%	45%
pН	60%	17%	0%
Specific Gravity	8%	17%	10%

Quest Diagnostics

Invalid Reasons: GW

	2004	2005	2006	Jan-Feb 2007
N (Thousands)	5.6	9.2	9.7	1.3
Bottle	1.6%	0.8%	1.5%	1.6%
Characteristics	0.9%	0.3%	0.7%	0.7%
Creatinine	12%	7%	12%	8%
GCMS	15%	6%	6%	8%
Immunoassay	22%	16%	16%	16%
Oxidant Activity	13%	23%	17%	18%
pН	33%	19%	19%	13%
Specific Gravity	8%	32%	28%	31%

Quest Diagnostics



Alternative Specimens & Technologies

- Specimens
 - Hair
 - ◆ Oral-Fluid
 - Sweat
- Technologies
 - ◆ POCT
 - IITF

3/6/200



Oral-Fluid vs. Urine

(January 2005 - December 2006)

Ora	ıl-Fluid Uri	ne GW
N (Millions)	~2	~14
Positive	4.0%	4.4%
BY DRUG		
Amphetamines	0.16%	0.46%
Methamphetamin	e 0.33%	N/A
Cocaine	1.04%	0.73%
Marijuana	2.12%	2.45%
Opiates	0.40%	0.32%
PCP	0.02%	0.02%

3/6/2007



Oral-Fluid Positive Opiates Frequency

(as Percentage of Opiate Positive Specimens)

	2003	2004	2005	2006
Codeine	21%	13%	12%	12%
Morphine	5%	9%	5%	6%
6-MAM	3%	3%	2%	2%
Hydrocodone	78%	81%	84%	83%

3/6/200



Quest Diagnostics	Questions ?		
Quest	Quest Diagnostics	S *	